Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. Lantern Pharma's [[LP-184]]: Utilizing their AI platform, RADR®, Lantern Pharma has developed LP-184, a drug candidate that has received Fast Track Designation from the FDA for glioblastoma treatment. LP-184 is currently in Phase 1A clinical trials, showing promise in penetrating the blood-brain barrier and targeting tumor cells effectively. lp-184.txt Last modified: 2025/02/26 22:50by 127.0.0.1